JAMES GOYDOS: RESEARCH TRIALS RECORD CANCER GROWTH ARREST

James Goydos, MD is widely recognized as a leading expert in melanoma research and surgical oncology. In his over 20 years of experience as a surgeon, he has conducted and published research that has directly translated into patient care, clinical trials, and cutting-edge treatment modalities. James Goydos' research and clinical trials have shown recorded growth arrest in melanoma cells, transforming the area of cancer genomics. 

Goydos is  deeply committed to his passion for educating tomorrow's professionals with his decades of experience as a Professor of Surgery and researcher. Goydos is an advocate for patient privacy and has been recognized for his leadership in patient care  by the Cancer Institute of New Jersey Melanoma Research Foundation. By 2020, his work with Melanoma research, innovative trials, and talent as a Professor have led him to record numerous awards as a Top Doctor in Cancer Care in New Jersey and New York. 

James Goydos is an academic surgeon specializing in Surgical Oncology. He is an experienced Professor Of Surgery and researcher with a demonstrated history of leading clinical trials and working in the medical industry.  His work has transformed the field of melanoma, with clinical trials recording the arrest of cancer cell growth. He is a strong education professional with a Doctor of Medicine (M.D.) from Rutgers, Robert Wood Johnson Medical School. 

Recognized for his leadership in patient care by the Melanoma Research Foundation and The Cancer Institute of New Jersey (CINJ), James Goydos is a leading expert in his field. Throughout his experience, he has been consistently awarded for being a top doctor for cancer care.  

Goydos helped to build the first clinical program focused on the treatment of patients with melanoma, other advanced cancers of the skin, and soft tissue sarcomas in New Jersey.  

Since completing his training as a Surgical Resident at the University of Connecticut and as a Surgical Oncology Fellow at The University of Pittsburgh he has had a strong interest in melanoma research. He is a National Cancer Institute (NCI)-funded investigator. Many of his collaborative laboratory discoveries have been translated into clinical trials for patients with melanoma.

James Goydos is the author or co-author of more than 80 peer-reviewed publications, review articles, book chapters, and published abstracts. He currently serves on the editorial board of the journal Clinical Cancer Research. 

As an experienced surgeon, professor, and medical researcher, James Goydos has recorded several awards recognising his expertise as a Top Doctor for Cancer in the New York Metro and New Jersey. He is an advocate for patient privacy has also been honoured by the Melanoma Research Foundation for his leadership in patient care. 

Dedicated to educating tomorrow's surgeons, James Goydos consistently seeks opportunities to mentor medical student researchers. As a Professor of Surgery, he  worked with numerous students in their third and fourth years as an overall advisor, guiding them through their clinical clerkships and helping with their applications to residency programs.

 He has an excellent record of resident and medical student teaching in the operating room, at the bedside, and in a laboratory setting. He has taught Surgical Residents during their research year(s), Graduate Students in the Rutgers School of Biomedical Sciences, and Medical Students participating in the Master of Clinical and Translational Science Program of the Rutgers Graduate School of Biomedical Sciences Program. 

Throughout his tenure as a surgeon, researcher, and Professor of Surgery, James Goydos  has lectured at top-tier medical schools, including Princeton University. He has also been invited as a guest speaker at numerous conferences, including the Mollie Biggane Melanoma Foundation Education Symposium,  the Melanoma and the Skin Cancer Patient and Caregiver Symposium  at Rutgers Cancer Institute of New Jersey, and more. Many of these events were filmed, providing access to patients to help them understand how medical professionals continue to investigate how to arrest tumor growth, so that melanoma doesn't become a death sentence.